RESIDENTS PAGE
Year : 2016 | Volume
: 61 | Issue : 5 | Page : 550--553
Belimumab in systemic lupus erythematosus
Ankita Srivastava
Department of Skin and VD, RUHS College of Medical Sciences and Government RDBP Jaipuria Hospital, Jaipur, Rajasthan, India
Correspondence Address:
Ankita Srivastava
Department of Skin and VD, RUHS College of Medical Sciences, Jaipur, Rajasthan
India
Belimumab is the only approved biological agent for the treatment of systemic lupus erythematosus (SLE). It is a fully humanized IgG1γ monoclonal antibody directed against soluble B lymphocyte stimulator (BLyS). It is indicated as an add-on therapy for the treatment of adult patients with active, autoantibody-positive SLE, who are receiving standard therapy. Belimumab is generally well-tolerated, common adverse effects include infections, infusion reactions, hypersensitivity, headache, nausea, and fatigue. Psychiatric events including suicidal tendency, progressive multifocal leukoencephalopathy and malignancies too have been reported. Apart from SLE, the drug is also being tried for other autoimmune disorders.
How to cite this article:
Srivastava A. Belimumab in systemic lupus erythematosus.Indian J Dermatol 2016;61:550-553
|
How to cite this URL:
Srivastava A. Belimumab in systemic lupus erythematosus. Indian J Dermatol [serial online] 2016 [cited 2023 Nov 30 ];61:550-553
Available from: https://www.e-ijd.org/article.asp?issn=0019-5154;year=2016;volume=61;issue=5;spage=550;epage=553;aulast=Srivastava;type=0 |
|
|
|
